The Indian markets saw modest gains with the Sensex up 0.67% and Nifty up 0.68%. The IT and media sectors saw the largest increases of over 2%. Meanwhile, reliance and power sectors declined over 1%. In Europe, the FTSE rose slightly while the CAC and DAX fell. Domestically, Sterlite plans a large expansion of its copper plant in Tamil Nadu. NTPC and Coal India remain in a dispute over unpaid coal dues. ONGC's cash reserves will be depleted after acquiring an IOC stake. Aurobindo signed a deal to acquire European assets and Biocon launched a new breast cancer biosimilar.

1. Corporate Newsletter
20th January 2014
SWASTIKA INTELLIGENCE GROUP
MARKET SNAPSHOT
INDIAN MARKETS
INDICES
SENSEX
NIFTY
NIFTY-50
Current Val.
21205.05
6303.95
Points
+141.43
+42.30
% Change
+0.67
+0.68
High
21221.37
6307.45
Low
21001.13
6243.35
Prev. Close
21063.62
6261.65
Sector
NSE SECTORAL INDICES
Current Value % Change
IT
MEDIA
SERVICE
FMCG
BANK NIFTY
AUTO
REALTY
FINANCE
INFRA
METAL
PHARMA
ENERGY
10,154.00
1,784.80
7,789.90
17,122.00
11,007.50
5,239.45
170.95
4,631.50
2,325.20
2,409.25
7,812.60
7,764.15
+2.73
+1.41
+1.32
+1.17
+0.88
+0.80
+0.74
+0.40
+0.40
-0.19
-0.04
-0.75
EUROPEAN MARKETS UPDATE AT 4:30 PM
INDICES
Last Closed
Change
FTSE
6,831.64
+2.34
CAC
4,327.01
-0.49
DAX
9,726.87
-16.09
Nifty Top Gainers
Symbol
LTP
TCS
WIPRO
HCLTECH
INDUSINDBK
SSLT
Prev. Close
% Change
2,213.05
552.70
1,379.65
423.35
200.60
+5.51
+3.85
+3.71
+2.75
+2.44
2,334.90
574.00
1,430.85
435.00
205.50
Nifty Top Losers
Symbol
LTP
RELIANCE
TATAPOWER
GRASIM
BHARTIARTL
NMDC
Prev. Close
% Change
884.75
78.35
2,622.00
310.90
145.50
-1.89
-1.15
-1.11
-1.05
-0.93
868.00
77.45
2,593.00
307.65
144.15
CURRENCY UPDATE (RBI Reference Rate)
ADVANCES DECLINES UNCHANGED
NSE
778
651
92
/$
/£
/€
/100 ¥
17th Jan
61.5325
100.7349
83.8395
58.7700
20th Jan
61.6345
101.2532
83.4245
59.1900
Swast
astika Intelligence Group,
1st Floor, Bandukwal Building, British Hotel Lane, Fort Mumbai
ala

2. Corporate Newsletter
20th January 2014
SWASTIKA INTELLIGENCE GROUP
NEWS UPDATES
Sterlite to take up Rs 2,500-cr expansion plan in Tamil Nadu The $15 billion Vedanta Group's natural
resources company set to take a Rs 2500 crore expansion, including to double the copper manufacturing capacity
and set up 2x80 Mw power projects, at its copper smelter plant at Tuticorin, Tamil Nadu. The plant, located on the
Southern tip of the State, earlier faced legal battles over alleged environment issues. Post the proposed expansion,
this plant will be Asia's largest copper manufacturing facility in a single location. The company hopes that in the
next six months all the formalities and legal issues will be sorted out and post which the expansion will be taken
up.
Power producer NTPC appears determined not to clear dues of about Rs 2,000 crore to the monopoly miner Coal
India (CIL) without third-party sampling of coal, indicating a protracted tussle ahead over the quality of coal that
had led to a stand-off between the two state-owned firms for much of last year. Coal produced from almost all the
mines of Eastern Coalfields is sampled by an independent party before it is dispatched to NTPC's thermal power
plants, NTPC recently paid CIL 1,000 crore, following a decision taken at a meeting held in the finance ministry
after its dues touched 3,000 crore.
The decision to buy stake in Indian Oil Corp will leave ONGC with only Rs 2500 crore in its cash reserve, The
company had a cash balance of over Rs 13,200 crore at the beginning of the year, He does not think buying stake
in IOC at this point is a bad idea. Following a weak response to the proposed divestment in IOC, and also
opposition from the OIL ministry on selling stake at depressed valuations, the government has decided to ask
state-owned companies ONGC and Oil India to pick up stake in IOC. This is being done so as to enable the
government to raise cash to bridge the fiscal deficit and meet the 4.8% target for the year.
Aurobindo Pharma The generic drug maker has signed a binding offer agreement to acquire commercial
operations of Dublin-based Actavis in seven Western European countries. Closing of the transaction is conditional
on certain anti-trust approvals and completion of employee consultation processes, without disclosing the
financial details of the deal. It expects to acquire personnel, commercial infrastructure, products, marketing
authorisations and dossier licence rights in seven European countries.
Biocon introduced 'CANMAb' (150 milligram (mg)/ 440 mg), a biosimilar trastuzumab for the treatment of HER2positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global
partnership, is the world's first biosimilar version of Herceptin and is being introduced for the benefit of patients
in India. CANMAb's 150 milligram (mg) formulation, priced at Rs 19,500 per vial, will allow extra savings to
patients as they can buy smaller quantities as per their requirement.
Citing unfavourable market conditions, mid-size private lender DCB Bank has said it will seek more time from the
Reserve Bank to bring down the promoters' stake to under 10 per cent. The rest of stake in the lender (formerly
Development Credit Bank) is with public, institutions and foreign investors. Akfed is a global enterprise dedicated
to promoting entrepreneurship and building economically-sound companies.
Swastika Intelligence Group,
1st Floor, Bandukwala Building, British Hotel Lane, Fort Mumbai

3. Corporate Newsletter
20th January 2014
SWASTIKA INTELLIGENCE GROUP
Disclaimer: This document is solely for the personal information of the intended recipient and must not be exceptionally used as the basis for any investment
decision. Nothing in this document should be construed as investment, Legal, taxation or financial advice. Swastika Investmart Ltd. is not soliciting any action based
upon it. Each recipient of this document should make necessary investigations as they consider important to arrive at an independent evaluation of an investment in
the securities of the companies referred to in this document (including the merits and risks involved). This report has been made based on information that we
consider reliable and are publicly available but we do not state that it is accurate or complete and it should not be solely relied upon such, as this document is for.
Swastika Investmart Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are
inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may
or may not subscribe to all the views expressed within this document.
Swastika Investmart Limited or any of its affiliates/ group companies, or employees shall not be in any way held responsible for any loss or damage that may arise to
any person from any inadvertent error in the information contained in this report.
Swastika Investmart Limited has not independently verified the information contained in this document. Accordingly, we cannot testify, nor make any
representation or warranty, express or implied, to the accuracy, contents or data contained within this document. This document is being supplied to you solely for
your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly.
Report Prepared by
Saloni Gupta
RESEARCH TEAM
Santosh Sahu
Santosh Meena
Amit Khare
Vishnu shreekar
Sonakshi Bahety
Designation
Research Associate
SWASTIKA INTELLIGENCE GROUP
Research Head
Derivatives & Technical Analyst
Commodity Analyst
Commodity Analyst
Research Associate
E-mail ID
salony.gupta@swastika.co.in
research@swastika.co.in
santosh.sahu@swastika.co.in
santosh.meena@swastika.co.in
amit.khare@swastika.co.in
vishnu.shreekar@swastika.co.in
sonakshi.bahety@swastika.co.in
Swastika Intelligence Group,
1st Floor, Bandukwala Building, British Hotel Lane, Fort Mumbai